1. Bernard GR, Vincent JL, Laterrre PF et al. (2000) Efficacy abd safety of recombinant human activated protein C for severe sepis. N Engl J Med 10:699–709
2. Carmassi F, De Negri F, Morale M et al. (1997) Antithrombotic and antifibrinolytic effects of antithrombin III replacement in liver cirrhosis (letter). Lancet 349:1069
3. Chang P (2004) New anticoagulants for venous thromboembolic disease. Drugs 7:50–57
4. Collins PW (2003) Management of acquired haemophilia A — more questions than answerts. Blood Cogaul Fibrinolysis 14(Suppl 1):S23–27
5. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigar A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL (2003) Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 29: 894–903